1. Home
  2. OI vs NRIX Comparison

OI vs NRIX Comparison

Compare OI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$14.97

Market Cap

2.0B

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.36

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
NRIX
Founded
1903
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OI
NRIX
Price
$14.97
$19.36
Analyst Decision
Buy
Strong Buy
Analyst Count
7
13
Target Price
$16.29
$27.46
AVG Volume (30 Days)
2.5M
1.9M
Earning Date
02-03-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
$83,687,000.00
Revenue This Year
$1.41
$59.40
Revenue Next Year
$1.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.32
52 Week Low
$9.23
$8.18
52 Week High
$16.04
$22.50

Technical Indicators

Market Signals
Indicator
OI
NRIX
Relative Strength Index (RSI) 61.91 63.80
Support Level $14.47 $17.44
Resistance Level $15.34 $19.67
Average True Range (ATR) 0.43 1.14
MACD -0.04 -0.20
Stochastic Oscillator 58.33 37.95

Price Performance

Historical Comparison
OI
NRIX

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: